Commissioner National Priority Voucher CNPV Pilot

Key Takeaways

• FDA launched the CNPV Pilot in June 2025 to compress review timelines for products tied to five national priorities.
• Vouchers are nontransferable and pair enhanced communications and rolling review with a 1–2 month target after filing.
• FDA held a June 4, 2026 public hearing and accepted written comments through June 29, 2026.
• By May 8, 2026, FDA said Bizengri (zenocutuzumab-zbco) was the seventh approval under the pilot; earlier CNPV approvals are listed on the program page.

CNPV Pilot at a glance

Field	Detail
Program	Commissioner's National Priority Voucher (CNPV) Pilot
Regulator	U.S. Food and Drug Administration (FDA)
Announced	June 2025
Review target	Approximately 1–2 months from filing to action
Priorities	Five: crisis response, breakthrough innovation, unmet need, onshoring/supply chain, affordability
Voucher rules	Nontransferable; generally initiate within two years of issuance
Public input	Hearing June 4, 2026; written comments through June 29, 2026

What is the Commissioner National Priority Voucher CNPV Pilot?

According to FDA's CNPV Pilot program page, the pilot explores a collaborative, tumor board–style review to accelerate applications that match one of five critical U.S. national health priorities. Vouchers may cover a company's specific drug or biologic application, or manufacturing or efficacy supplements.

FDA says pre-market applications in the program still face the same statutory and regulatory approval requirements as other filings. Approval decisions stay with the relevant Center; the CNPV Review Council makes non-binding recommendations after multidisciplinary discussion.

Which five national priorities qualify?

FDA lists five priority buckets on the program page:

• Public health crisis response — products for urgent or emerging threats, or with large population impact.
• Innovative breakthrough therapies — transformative treatments with novel mechanisms that change disease management.
• Large unmet medical needs — therapies where existing options inadequately address outcomes.
• Onshoring and supply chain resilience — development or manufacturing that strengthens U.S. capacity and reduces foreign dependence.
• Affordability — approaches that improve value through lower system cost or better access.

FDA's CNPV FAQs note the pilot covers drugs, biologics, and certain combination products, and does not replace Fast Track, Breakthrough Therapy, Accelerated Approval, or Priority Review.

How fast is CNPV review compared with other pathways?

FDA contrasts the pilot with conventional timelines: a 1–2 month target versus 6+ months for many reviews, with enhanced pre-submission engagement and rolling review. FAQs describe roughly 60 days of pre-submission work, an abbreviated filing check, then about 1–2 months of application review.

In its March 20, 2026 public-meeting announcement (updated April 1 for the June 4 date), FDA said it had awarded vouchers for 18 products and granted four approvals at that time, including two oncology actions 44 and 55 days after filing.

What feedback did FDA seek in June 2026?

FDA published a Federal Register notice seeking comment and set a June 4, 2026 hearing at White Oak with virtual participation. Topics include eligibility criteria, voucher selection, sponsor responsibilities, pre-submission requirements, review procedures, the CNPV Review Council's role, and implementation.

Requests to speak were due April 24; written comments were due June 29, 2026. Sponsors still may submit statements of interest via the CNPV submission pathway, and FDA says it remains focused on pilot implementation while it may award additional vouchers.

What CNPV approvals has FDA listed so far?

The program page catalogs approvals from the first CNPV action on December 9, 2025, through later 2026 decisions, including a first new molecular entity, higher-dose semaglutide, and a gene therapy for genetic hearing loss. On May 8, 2026, FDA's seventh CNPV approval announcement covered Bizengri (zenocutuzumab-zbco) for NRG1 fusion-positive cholangiocarcinoma after prior therapy.

That press release again flagged the June 4 hearing and June 29 comment deadline, underscoring that the agency is collecting external input while approvals continue under the pilot.

What remains unsettled for sponsors?

CNPVs are not transferable to another company, though they survive ownership changes, and FDA generally expects the voucher process to start within two years of issuance. Draft guidance for external stakeholders was still forthcoming as of the FAQs, and FDA is enhancing pre-submission expectations (CMC, facilities, and related data at least 60 days before a complete application, or 120 days if foreign inspections are anticipated).

Sponsors should not treat a voucher as a guarantee of approval or as a substitute for meeting safety and effectiveness standards. Questions can go to [email protected].

Related NovaPharma coverage

• FDA guidance on human factors in marketing submissions
• Moderna mRNA-1083 Phase 3 flu-COVID immune response
• J&J Phase 3 TREMFYA ulcerative colitis data
• FDA Salmonella moringa leaf powder recall

Frequently Asked Questions

Primary Sources

1. FDA: Commissioner's National Priority Voucher (CNPV) Pilot Program
2. FDA: FAQs on the Commissioner's National Priority Voucher Pilot Program
3. FDA: Public meeting scheduled for the CNPV Pilot Program
4. FDA: Seventh approval under the National Priority Voucher Pilot Program